Skip to main content




Malaysia approves Sinovac, AstraZeneca COVID-19 vaccines for use

Malaysia approves Sinovac, AstraZeneca COVID-19 vaccines for use

A medical worker administers a COVID-19 vaccine in Kuala Lumpur, Malaysia on Mar 1, 2021. (Photo: Reuters/Lim Huey Teng)

KUALA LUMPUR: Malaysia on Tuesday (Mar 2) granted conditional approval for the use of vaccines made by UK firm AstraZeneca and China's Sinovac, just days after launching its nationwide COVID-19 inoculation programme.

Malaysia began its vaccination drive on Feb 24 using a shot developed by US drugmaker Pfizer and German partner BioNTech, as it tries to rein in a spike in infections and help revive an economy that recorded its worst slump in more than two decades last year.

The conditional approval means Malaysia will use the vaccines developed by Astrazeneca and Sinovac, but both firms - along with Pfizer - will be required to provide additional data on rolling submissions to ensure the vaccines' effectiveness and safety, health director-general Noor Hisham Abdullah said in a statement.

READ: COVID-19: Curbs to be eased in Malaysia as Selangor, KL, Johor and Penang return to CMCO

READ: COVID-19: Johor hopes talks on reopening Malaysia-Singapore borders will resume

Health authorities are also evaluating the COVID-19 vaccine produced by Russia's Gamaleya Research Institute, and the local bottling facility for Sinovac's vaccine, Noor Hisham said.

Sinovac signed a deal with Malaysia's Pharmaniaga, which will carry out a fill-and-finish process for the vaccine's distribution in Malaysia, before later manufacturing it locally.

Malaysia aims to vaccinate at least 80 per cent of its population of about 32 million by February next year.

Last month, the government said it had secured 66.7 million vaccine doses, enough to more than cover its population.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: 

Source: Reuters/zl


Also worth reading